MiNK Therapeutics, Inc.
INKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $215 | $205 | $122 | $78 |
| Gross Profit | -$215 | -$205 | -$122 | -$78 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,336 | $15,490 | $23,115 | $13,966 |
| G&A Expenses | $4,314,164 | $7,431 | $0 | $0 |
| SG&A Expenses | $4,099 | $7,431 | $7,712 | $4,562 |
| Sales & Mktg Exp. | -$4,310,065 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$205 | $0 | $0 |
| Operating Expenses | $10,435 | $22,716 | $30,828 | $18,528 |
| Operating Income | -$10,650 | -$22,921 | -$30,949 | -$18,606 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$135 | $463 | $2,958 | -$11,606 |
| Pre-Tax Income | -$10,785 | -$22,458 | -$27,991 | -$30,213 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10,785 | -$22,458 | -$27,991 | -$30,213 |
| % Margin | – | – | – | – |
| EPS | -2.9 | -6.54 | -8.31 | -9.03 |
| % Growth | 55.7% | 21.3% | 8% | – |
| EPS Diluted | -2.8 | -6.54 | -8.31 | -9.03 |
| Weighted Avg Shares Out | 3,744 | 3,436 | 3,367 | 3,348 |
| Weighted Avg Shares Out Dil | 3,863 | 3,436 | 3,367 | 3,348 |
| Supplemental Information | – | – | – | – |
| Interest Income | $173 | $463 | $253 | $2 |
| Interest Expense | $0 | $0 | $253 | $2,432 |
| Depreciation & Amortization | $215 | $205 | $122 | $78 |
| EBITDA | -$10,569 | -$22,253 | -$27,869 | -$27,703 |
| % Margin | – | – | – | – |